Oncologica UK
Hospitals and Health Care • 
Saffron Walden, England, United Kingdom • 21-50 Employees
Company overview
| Headquarters | Chesterford Research Park, The Newnham Building, Suite 2, Chesterford, Cambridgeshire CB10 1XL, GB |
| Phone number | +441223785327 |
| Website | |
| NAICS | 62 |
| SIC | 807 |
| Keywords | Research And Development, Drug Discovery, Immunotherapy, Cancer Treatments, Molecular Pathology, Dna & Rna Analysis, Molecular Tissue Analytics, Next Generation Sequencing Ngs, Precision Oncology, Targeted Therapies, Tumour Profiling, Cancer Dna Profiling, Coronavirus Variant Sequencing, Covid-19 Pcr Testing, Covid-19 Variant Detection, Covid-19 Variant Identification, Genomic Cancer Diagnostics, Polymerase Chain Reaction Tests, Travel Pcr Test Kits, Genomic Sequencing Strategies |
| Founded | 2014 |
| Employees | 21-50 |
| Socials |
Key Contacts at Oncologica UK
Gareth Haydn Williams
Co-Founder And Medical Director At Oncologica Uk Ltd
Marco Loddo
Co-Founder And Scientific Director
Oncologica UK Email Formats
Oncologica UK uses 2 email formats. The most common is {first name}.{last name} (e.g., john.doe@oncologica.com), used 65% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}.{last name} | john.doe@oncologica.com | 65% |
{first initial}.{last name} | j.doe@oncologica.com | 35% |
About Oncologica UK
Oncologica is a world leading precision cancer medicine and Covid-19 testing and genomic sequencing laboratory based in Cambridge, UK. Our personalised cancer DNA profiling is used to precisely identify the most appropriate clinical targeted therapies and/or immunotherapies which can be used to treat patients as an alternative to chemotherapy. Our molecular Next Generation Sequencing capabilities are used to sequence tumour DNA and Covid-19/ SARS-CoV-2 for virus mutations. SARS-CoV-2 testing, and sequencing is used to identify high risk Covid-19 variants which can potentially bypass the vaccine. Oncologica’s NGS DNA profiling covers 505 genes with linkage to over 750 targeted therapies to provide patients and clinicians with detailed genomic blueprints that optimize therapy choices and improve outcomes. Oncologica also undertakes Contract Research supporting biomarker development programmes, clinical trials, and the validation of new diagnostic testing platforms. Our in-house R&D activities focus on the development of novel cancer genomic based diagnostic and therapeutic approaches. Our government approved Oncofocus and Coronofocus lab tests are used by healthcare providers the private sector, businesses, transport, and educational institutions. Personalised genomic data helps empower patients and clinicians to increase treatment efficacy and improve human health.
Oncologica UK revenue & valuation
| Annual revenue | $5,000,000 |
| Revenue per employee | $162,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Hospitals and Health Care industry and current estimated revenues | $16,000,000 |
| Total funding | No funding |
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Oncologica UK has 12 employees across 4 departments.
Departments
Number of employees
Funding Data
Oncologica UK has never raised funding before.
Oncologica UK Tech Stack
Discover the technologies and tools that power Oncologica UK's digital infrastructure, from frameworks to analytics platforms.
CDN
JavaScript frameworks
Page builders
Tag managers
Programming languages
Live chat
Security
Miscellaneous
JavaScript frameworks
CMS
Miscellaneous
Analytics
Argentina
Germany
United States
Denmark
New Zealand
South AfricaFrequently asked questions
4.8
40,000 users
